Junshi Biosciences IPO Preview: A Sense of Déjà Vu Without the Excitement
Shanghai Junshi Bioscience Co. Ltd. (1387344D CH) is a biopharmaceutical company which is developing a pipeline of 13 biologic drugs, including...
406 Views
Morningstar Management Behind the Moat 2018: Conference Highlights
Morningstar and PitchBook hosted the 10th annual Management Behind the Moat Conference in Chicago on Nov. 7 and 8, offering our institutional...
718 Views
U.S. Equity Strategy & Sector Commentaries: Defensive Sectors Leading = Unhealthy Market
The “Big” rally has now faded less than a week from its start. While many point to a robust economy, strong GDP, and a strengthening U.S. dollar as...
389 Views
Kyorin 1H FY18 (YE Mar'19) Results - First Glance
Key highlights Overall sales (¥50b) stayed flat as brisk uptake of Flutiform (+13% to ¥6.1b), Desalex (+200% to ¥2.8b) and Nasonex (after Merck...
345 Views
Eisai 1H FY18 (YE Mar'19) Results - First Glance
Key highlights Lenvima, Eisai’s key revenue driver, performed across regions (+43% to ¥14.3b in the US, +170% to ¥4.3b in Japan and +40% to ¥3.7b...
428 Views